Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)

• Status: Completed
• Trial end date: 2017-07-05

Summary

Evaluation weather early chemotherapy attempts for remission induction can improve the results of patients with Acute Myeloid Leukemia (AML), as compared to the standard group.

• Phase: Phase 3

Details

• Lead Sponsor: Prof. Dr. Wolfgang Hiddemann
• Collaborator: Kompetenznetz Leukämien
• Treatments: Daunorubicin; Mitoxantrone